Thomas Burris, Ph.D., Chair and Professor of Pharmacology and Physiology, published a paper in Biochemical Pharmacology on studies of the nuclear receptor, REV-ERB, and its role in regulation of LDL cholesterol.
Researchers used a mouse model to study the effects of a REV-ERB agonist, SR9009, and showed that it reduced plasma cholesterol in wild-type and LDLR null mice. They also showed that mice with no expression of REV-ERB has increased plasma LDL. Researchers showed that REV-ERB binds to the majority of genes related to cholersterol biosynthesis and suppresses expression of these genes, making it a potential target for treatment of LDL levels in human disease.
For more information, read the full article in Newslink.